Monitor for final Cohort 4 data release in Q4 2026 and initial Cohort 5 data in H1 2027 — these are the next binary catalysts. The PanCAN grant payment is a modest non-dilutive cash inflow but the amount is undisclosed and likely immaterial relative to the company's cash burn.
Price Chart
Executive Summary
Oncolytics Biotech provided an update on its GOBLET Phase 1/2 study, announcing it expects to receive the final grant payment from the Pancreatic Cancer Action Network (PanCAN) later this quarter as part of wind-down activities. The company also guided for final Cohort 4 results in Q4 2026 and initial Cohort 5 results in the first half of 2027, noting that median overall survival in Cohort 4 exceeds expectations and that each cohort that enrolled the required number of patients met its pre-specified success criteria for efficacy. This is a routine operational update with no new financial data or binary catalyst — the data readouts remain months away.
Key Facts
- Final PanCAN grant payment expected later this quarter as part of GOBLET wind-down activities
- Final Cohort 4 results expected in Q4 2026; initial Cohort 5 results expected in H1 2027
- Each cohort that enrolled the required number of patients met its pre-specified success criteria for efficacy
- Median overall survival in Cohort 4 exceeds expectations, per the Chief Medical Officer
- GOBLET study enrollment is complete; infrastructure is being wound down while patients continue treatment and follow-up
Financial Impact
Final PanCAN grant payment expected this quarter — amount undisclosed. No other financial figures provided.
Risk Factors
- Cohort 5 data may be delayed as multiple patients continue treatment and follow-up
- No revenue or earnings reported — pre-revenue clinical-stage company with no near-term commercialization path
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001129928-26-000072 |
| Document: gobletc5pancanupdate.htm | 0001129928-26-000072 |
| Document: 0001129928-26-000072-index-headers.html | 0001129928-26-000072 |
| Document: 0001129928-26-000072-index.html | 0001129928-26-000072 |
| Document: 0001129928-26-000072.txt | 0001129928-26-000072 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 8-K | $0.4858 | awaiting T+20 | — | $0.4671 (−3.85%) |
Oct 27, 2026 today | Press Release | $0.4700 | awaiting T+20 | — | $0.4671 (−0.62%) |
Oct 20, 2026 7d ago | 8-K | $0.4986 | awaiting T+20 | — | $0.4671 (−6.32%) |
Oct 20, 2026 7d ago | Press Release | $0.4986 | awaiting T+20 | — | $0.4671 (−6.32%) |
Oct 14, 2026 13d ago | 8-K | $0.5382 | awaiting T+20 | — | $0.4671 (−13.21%) |
Oct 13, 2026 14d ago | 8-K | $0.4900 | awaiting T+20 | — | $0.4671 (−4.67%) |
Oct 6, 2026 20d ago | DEFA14A | $0.6000 | awaiting T+20 | — | $0.4671 (−22.15%) |
Oct 6, 2026 20d ago | DEF 14A | $0.6000 | awaiting T+20 | — | $0.4671 (−22.15%) |
Sep 29, 2026 28d ago | 8-K | $0.6745 | awaiting T+20 | — | $0.4671 (−30.75%) |
Sep 28, 2026 29d ago | 8-K | $0.6630 $0.4732 | ▼ −28.63% | ▼ −28.60% | $0.4671 (−29.55%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers